Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.47 | N/A | +15566.67% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.47 | N/A | +15566.67% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed cautious optimism about the future, focusing on the significant EPS surprise. However, they did not provide any revenue guidance.
Management highlighted the strong performance in EPS despite the lack of revenue guidance.
They emphasized ongoing efforts to enhance operational efficiency.
The earnings report shows that Soleno Therapeutics delivered a surprising EPS performance, significantly exceeding expectations. However, the stock fell by 2.74%, likely due to the absence of revenue figures and guidance, which may have left investors uncertain about future growth prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SBA COMMUNICATIONS C Class A REIT
Nov 3, 2025